- Home
- TPIC vs CNTX Comparison
TPIC vs CNTX Comparison
Compare TPIC & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPIC
- CNTX
- Stock Information
- Founded
- TPIC 1968
- CNTX 2015
- Country
- TPIC United States
- CNTX United States
- Employees
- TPIC N/A
- CNTX N/A
- Industry
- TPIC Industrial Machinery/Components
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- TPIC Industrials
- CNTX Health Care
- Exchange
- TPIC Nasdaq
- CNTX Nasdaq
- Market Cap
- TPIC 65.6M
- CNTX 60.7M
- IPO Year
- TPIC 2016
- CNTX 2021
- Fundamental
- Price
- TPIC $0.73
- CNTX $0.84
- Analyst Decision
- TPIC Hold
- CNTX Strong Buy
- Analyst Count
- TPIC 6
- CNTX 5
- Target Price
- TPIC $1.86
- CNTX $6.50
- AVG Volume (30 Days)
- TPIC 684.9K
- CNTX 257.9K
- Earning Date
- TPIC 05-08-2025
- CNTX 05-07-2025
- Dividend Yield
- TPIC N/A
- CNTX N/A
- EPS Growth
- TPIC N/A
- CNTX N/A
- EPS
- TPIC N/A
- CNTX N/A
- Revenue
- TPIC $1,331,131,000.00
- CNTX N/A
- Revenue This Year
- TPIC $8.93
- CNTX N/A
- Revenue Next Year
- TPIC $9.59
- CNTX N/A
- P/E Ratio
- TPIC N/A
- CNTX N/A
- Revenue Growth
- TPIC N/A
- CNTX N/A
- 52 Week Low
- TPIC $0.64
- CNTX $0.55
- 52 Week High
- TPIC $5.75
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- TPIC 40.56
- CNTX 56.99
- Support Level
- TPIC $0.73
- CNTX $0.80
- Resistance Level
- TPIC $0.92
- CNTX $0.89
- Average True Range (ATR)
- TPIC 0.09
- CNTX 0.11
- MACD
- TPIC 0.01
- CNTX 0.03
- Stochastic Oscillator
- TPIC 31.10
- CNTX 73.80
About TPIC TPI Composites Inc.
TPI Composites Inc is engaged in manufacturing composite wind blades. The company operates in wind energy and transportation industries where it manufactures structures for a bus, rail, theme parks, and trucks. Geographically the segments are divided into the U.S, Asia, Mexico, EMEA and India where the Mexico segment derives a majority of revenue.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.